JAK2/IDH-mutant–driven myeloproliferative neoplasm is sensitive to combined targeted inhibition

Por McKenney, Anna Sophia, Lau, Allison N., Somasundara, Amritha Varshini Hanasoge, Spitzer, Barbara, Intlekofer, Andrew M., Ahn, Jihae, Shank, Kaitlyn, Rapaport, Franck T., Patel, Minal A., Papalexi, Efthymia, Shih, Alan H., Chiu, April, Freinkman, Elizaveta, Akbay, Esra A., Steadman, Mya, Nagaraja, Raj, Yen, Katharine, Teruya-Feldstein, Julie, Wong, Kwok-Kin, Rampal, Raajit, Heiden, Matthew G. Vander, Thompson, Craig B., Levine, Ross L.
Publicado no J Clin Invest (2018)

JAK2/IDH-mutant–driven myeloproliferative neoplasm is sensitive to combined targeted inhibition

Por McKenney, Anna Sophia, Lau, Allison N., Somasundara, Amritha Varshini Hanasoge, Spitzer, Barbara, Intlekofer, Andrew M., Ahn, Jihae, Shank, Kaitlyn, Rapaport, Franck T., Patel, Minal A., Papalexi, Efthymia, Shih, Alan H., Chiu, April, Freinkman, Elizaveta, Akbay, Esra A., Steadman, Mya, Nagaraja, Raj, Yen, Katharine, Teruya-Feldstein, Julie, Wong, Kwok-Kin, Rampal, Raajit, Vander Heiden, Matthew G., Thompson, Craig B., Levine, Ross L.
Publicado no J Clin Invest (2018)